Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : NVS save search
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
ERAS | $1.79 0.0% 570K
|
|
| O: 2.99%
H: 2.03%
C: 0.58%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.02%
H: 0.24%
C: 0.01%
trials collaboration trial
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
Published: 2024-01-08 (Crawled : 07:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.89%
H: 0.12%
C: -0.17%
scemblix leukemia trial response molecular
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2023-12-11 (Crawled : 01:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.75%
H: 0.55%
C: 0.27%
fabhalta novartis trial results
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
Published: 2023-08-29 (Crawled : 12:00) - globenewswire.com
ERAS | $1.79 0.0% 570K
|
|
| O: 0.0%
H: 1.52%
C: -2.09%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.18%
H: 1.41%
C: 1.1%
tumors trial plus
Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
Published: 2023-07-12 (Crawled : 12:20) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: 0.26%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
hope beacon education novartis trial
Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
Published: 2023-06-12 (Crawled : 20:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.26%
H: 0.15%
C: -0.42%
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: -0.21%
H: 0.26%
C: -0.08%
bion-1301 nephropathy association renal trial therapeutics igan
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Published: 2023-05-23 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: -0.62%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -1.22%
GKOS | $96.5 1.44% 0.0% 700K
|
Health Technology
|
| O: -0.71%
H: 2.06%
C: -1.05%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -2.27%
H: 4.24%
C: -2.21%
ALC | $79.55 1.38% -0.25% 1.1M
|
Health Technology
|
| O: -0.51%
H: 0.02%
C: -3.25%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.31%
H: 0.26%
C: -1.34%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
OCUL | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
|
| O: 4.45%
H: 7.65%
C: 2.21%
GRFS | News | $6.29 -3.82% -3.97% 1.2M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -3.74%
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.61%
pharma disease pipeline set eye trial
Zollinger-Ellison Syndrome (Gastrinoma) Clinical Trial Analysis Report 2023: Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries
Published: 2023-05-12 (Crawled : 00:20) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
report trial
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Published: 2023-04-26 (Crawled : 15:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: -2.04%
breast asco cancer kisqali novartis trial
Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
Published: 2023-04-26 (Crawled : 10:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: -2.04%
transfusion novartis trial
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.37%
H: 0.2%
C: -0.79%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 6.51%
H: 1.75%
C: 1.4%
kisqali breast cancer novartis trial
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx® (Secukinumab)
Published: 2022-11-01 (Crawled : 11:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.47%
H: 0.09%
C: -0.55%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
bat2306 cosentyx solutions biosimilar trial
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
biosimilar trial positive
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Published: 2022-06-07 (Crawled : 15:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -2.41%
H: 0.65%
C: 0.42%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
scemblix novartis leukemia trial
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
Published: 2022-04-01 (Crawled : 16:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.64%
H: 0.6%
C: 0.57%
immunology trial positive
Non-alcoholic Steatohepatitis Clinical Trials Market Size Worth $4.2 Billion By 2030: Grand View Research, Inc.
Published: 2022-02-01 (Crawled : 11:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.58%
H: 0.0%
C: -1.59%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 0.89%
H: 0.59%
C: 0.41%
hepatitis als trials research trial clinical trials
Global CAR-T Cell Therapy Markets to 2026: Rising Clinical Trials and Development of New and Effective Therapy Options
Published: 2021-09-28 (Crawled : 16:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.12%
H: 1.77%
C: -0.99%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.16%
H: 0.04%
C: -0.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.09%
H: 0.93%
C: -0.26%
SGMO | $0.5143 6.02% 5.68% 1M
|
Health Technology
|
| O: -1.12%
H: 0.52%
C: -2.17%
AUTL | $4.51 -6.04% -6.43% 1.4M
|
Health Technology
|
| O: -2.67%
H: 1.27%
C: -5.48%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.38%
H: 1.16%
C: -0.01%
clinical trials therapy car-t trials trial t-cell
Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA
Published: 2021-08-03 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.3%
H: 0.17%
C: 0.17%
phase 3 trial order
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
Published: 2021-08-02 (Crawled : 17:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.33%
H: 0.15%
C: -0.16%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.24%
H: 2.2%
C: 1.07%
cardiovascular cardio trial enroll
Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Published: 2021-06-04 (Crawled : 13:15) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.55%
H: 0.41%
C: 0.0%
therapy cancer trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.